swiss drugmaker novartis announced 565bn euros 74bn Â£39bn purchases make sandoz unit worlds biggest generic producer
novartis last month forecast record sales 2005 said bought germanys hexal
acquired 677 hexals us affiliate eon labs offered buy remaining shares 31
novartis said would able make cost savings 200m year following acquisitions
novartis shares rose 1 5785 swiss francs early trading
deal see novartis sandoz business overtake israels teva pharmaceuticals worlds biggest maker generics
based 2004 figures newly merged producer would sales 5bn company estimated
novartis said would merge number departments adding may job cuts
strong growth outlook sandoz create jobs expected partially compensate necessary reductions work force firm said statement
generic drugs chemically identical expensive branded rivals
producers sandoz copy branded products usually patent protection expires sell cheaply pay research development cost
150 generic drugmakers worldwide analysts predicted consolidation market call fragmented
however analysts initially convinced deal
expensive acquisition birgit kuhlhoff sal oppenheim investment bank told reuters
find strange making acquisitions exactly markets suffered price pressure
